Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
about
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association studyMutation analysis of the MSMB gene in familial prostate cancer.Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk.Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis.Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.Active surveillance of early prostate cancer: rationale, initial results and future developments.Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial.Prostate cancer: screening approaches.Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring.A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival.A review of targeted screening for prostate cancer: introducing the IMPACT study.The spectrum of prostate cancer care: from curative intent to palliation.Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance.Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.Active surveillance vs radical prostatectomy.A personalised approach to prostate cancer screening based on genotyping of risk founder allelesUsing a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study.Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.What is low-risk prostate cancer and what is its natural history?Stage shift in PSA-detected prostate cancers - effect modification by Gleason score.Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study.Patient advocacy and patient centredness in participant recruitment to randomized-controlled trials: implications for informed consent.Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research.PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis.High-risk prostate cancer: the role of radical prostatectomy for local therapy.Measuring mortality reductions in cancer screening trials.Comparative effectiveness research in localized prostate cancer treatment.Publicly funded practice-oriented clinical trials: of importance for healthcare payers.Multigene panels in prostate cancer risk assessment: a systematic review.A novel randomised controlled trial design in prostate cancer.The use of prostate-specific antigen testing in men presenting with haematuria.Additional elastography-targeted biopsy improves the agreement between biopsy Gleason grade and Gleason grade at radical prostatectomy.Consideration of the likely benefit from implementation of prostate image-guided radiotherapy using current margin sizes: a radiobiological analysis.A model of the natural history of screen-detected prostate cancer.Genetic variants associated with predisposition to prostate cancer and potential clinical implications.Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry.
P2860
Q29417074-4104D1D1-4DEB-4EDF-9FE6-3606570CB894Q33630836-1B47FAB5-6496-4A14-9992-7ADD6BCDC602Q33728225-4C2148A4-BCA9-4969-B69C-00F845F8FE68Q33750148-54C18CC6-AB84-48AB-9E10-F55AF1589CBAQ33834396-49B438B8-DBC3-4E1D-A70E-FA996E2A8C63Q33864647-22A31CC0-FD8F-495D-B7C5-7E334F1E26F1Q35602297-2A12574F-80E5-4211-A0BC-52CC0F74875AQ35821211-4A0B6656-0ACC-4147-B91E-E39191F009C6Q36081080-9B68A5E1-8D47-4861-933F-7087F1FCA26DQ36322789-FEE85C6D-A09A-431D-904F-617468623511Q36520484-CE396956-B6AF-4A19-892D-927DEABEF97CQ36614192-EEE83C80-C8F9-40A4-9DAD-933C58FBD3DAQ36785878-219935BE-F4FD-4231-8CE3-430FE0466F28Q36801769-853323B3-0591-4808-B1AF-5FFD90F24FC2Q36833353-EB80D76C-772F-47E9-9210-3E243971A8B2Q36841565-E35CAA4A-5284-45FE-B983-6DC0BD86A6B7Q36861748-C03057F6-2C6A-4104-8BE0-B7A45A7DE55BQ36959139-8D89E090-87CF-47CB-86CA-024D76D449CBQ37035993-43073DFC-27BA-47DA-8EE2-A9D995532B39Q37160706-9279BEB7-6585-423F-8F95-DF77C2555DFBQ37196270-D3C3CD5C-7879-4CEB-AFA4-0F183EEA6B2DQ37248410-ACEAE06E-AAC7-4188-B895-15AEC75F6330Q37287476-B2E378F7-A992-4C20-96D6-932FC91E99A7Q37333681-986C69EE-EBF8-4568-AAF3-60BEBBC6788AQ37418508-69A0F98A-BD6B-4D3D-9717-EB90734E75B9Q37504669-A6FC8945-93AE-400D-A3D6-323D333A475BQ37861198-737DEEE3-5CC6-400F-BADC-3B13A57C7D29Q37882227-972D5B0D-3457-4081-AD4A-09A2D6FD2D1EQ38162919-956470FA-40FC-47F3-B58B-4CC50CF5676EQ38376709-C9367896-4255-49AA-BC90-3C9B4F39C073Q38596777-0ED65EEF-3615-4902-8CFC-825BA24DCFFDQ38874206-F8639A75-48C9-4FF7-BD5E-2BF3116D0BD4Q39771276-E7195FD5-390F-4FB9-A8E8-7A1C3690AE5BQ40415928-C771366A-8258-4AA2-A48F-646FDDB098AEQ41553976-8204344D-5E6D-4FC2-9E50-E1F0B9B0BA6AQ43199658-29000A6C-BF18-49AB-9CCA-B4B24B4B9596Q43415543-B354756D-C166-428A-B346-1E239A50E715Q43751214-C9D52CE2-CC57-40F2-8529-2F5D15BB0E78Q44205517-B45E24EF-2847-40D9-B856-CC8412F5C103Q44321478-E792585E-A0E8-4D24-8B4B-66595A4F261B
P2860
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
description
im Jahr 2003 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2003
@uk
name
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
@en
Prostate Testing for Cancer and Treatment
@nl
type
label
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
@en
Prostate Testing for Cancer and Treatment
@nl
prefLabel
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
@en
Prostate Testing for Cancer and Treatment
@nl
P2093
P356
P1476
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
@en
P2093
D. Gillatt
J. Donovan
L. Brindle
P356
10.3310/HTA7140
P577
2003-01-01T00:00:00Z